Mitochondrial Dysfunction in Renal Aging: A Vicious Cycle Driving Kidney Disease Progression
Wenpei Yu1, Qing Ouyang2, Weicen Liu2
1School of Clinical Medicine, Dazhou Vocational and Technical College, Dazhou, Sichuan Province, China.
Antioxidants & Redox Signaling
|March 27, 2026
Summary
Kidney aging is driven by mitochondrial dysfunction, creating a cycle of damage. New therapies targeting mitochondrial senescence are needed to prevent age-related kidney diseases.
Area of Science:
- Gerontology and Nephrology
- Mitochondrial Biology
- Cellular Senescence
Background:
- Aging populations face increased age-related diseases, particularly kidney decline.
- Mitochondrial dysfunction is a key driver of kidney aging and disease.
- Mitochondria are central to cellular metabolism, redox balance, and cell fate.
Purpose of the Study:
- To systematically summarize the associations and causal mechanisms of disrupted mitochondrial homeostasis in renal aging.
- To examine the role of mitochondria-associated senescence in acute kidney injury and chronic kidney disease.
- To highlight potential interventions targeting mitochondrial dysfunction and cellular senescence.
Main Methods:
- Literature review and synthesis of current research on mitochondrial dysfunction and kidney aging.
- Analysis of factors contributing to a vicious cycle promoting renal aging.
- Examination of mitochondria-associated senescence in kidney injury models.
Main Results:
- Dysregulated redox status, metabolic reprogramming, mtDNA abnormalities, impaired quality control, and calcium overload promote renal aging.
- Mitochondrial dysfunction and cellular senescence form a self-perpetuating cycle exacerbating kidney injury.
- Mitochondria-associated senescence plays a role in both acute and chronic kidney diseases.
Conclusions:
- Targeting mitochondrial dysfunction and senescence holds promise for treating age-related kidney diseases.
- Current interventions for mitochondrial aging in kidneys are underdeveloped and require clinical trials.
- Future research should focus on developing precise drugs for mitochondrial senescence to prevent kidney disease progression.
Keywords:
acute kidney injurycell senescencechronic kidney diseasemitochondrial dysfunctionrenal agingMore Related Videos
Related Concept Videos
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
316
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
316
Mitochondria
21.3K
Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
21.3K
Chronic Kidney Disease I: Introduction
1.1K
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
1.1K
Chronic Kidney Disease II: Clinical Manifestations
945
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
945
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
324
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
324
Electron Transport Chain: Complex I and II
19.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
19.5K


